Login | Register

Pulmonary Arterial Hypertension – Phase III SERAPHIN Outcome Study Meets Primary Endpoint

The initial analysis of Actelion's macitentan, a novel dual endothelin receptor antagonist that resulted from a tailored drug discovery process, has met its primary endpoint in a pivotal, long term, event-driven SERAPHIN Phase III trial...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *